Study: Adalimumab Effective in Maintaining Remission in Pediatric Crohn's
The results of a new study indicate Adalimumab, an anti-tumor necrosis factor antibody, is effective in maintaining remission in certain children with Crohn's disease, according to a news release.
The study was published in Gastroenterology, the journal of the American Gastroenterological Association.
This study, the largest double-blind study of an anti-TNF agent in children with Crohn's disease, found that more than 80 percent of children with moderate to severe Crohn's disease responded to the therapy within a month. By six months, about 34 percent of patients were in clinical remission, and after a year, more than 28 percent were in remission.
Related Articles on the American Gastroenterological Association:
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- 6 Ways for ASCs to Use EMR as a Marketing Tool
- 4 GI/Endoscopy-Related Devices Receive 510(k) Clearance in November
- Bascom Palmer Eye Institute to Expand With New Naples ASC, Medical Office Building
- La Peer Health Systems Opens Los Angeles Hernia Surgery Center
- Graymark Healthcare Changes Name to Foundation Healthcare